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Abstract
Background: Intravenous tranexamic acid (IV TXA) is one of the most effective agents in use for reducing blood
loss following total knee arthroplasty (TKA) but its safety regarding venous thromboembolic events (VTEs) remains
in question. The direct, local application of TXA may reduce systemic toxicity whilst maintaining good or better
bleeding control compared to IV TXA. The topical application of TXA via Hemovac drains has been reported
previously with good results. However, there are no data on peri-articular TXA injections during TKA.
Methods: We conducted an open randomized, pilot study of peri-articular vs. IV TXA in 60 patients undergoing
TKA. 30 patients received either: (i) 750 mg peri-articular TXA into the medial, lateral capsules and the quadriceps
tendon prior to capsular closure and tourniquet deflation (group1), or (ii) 750 mg of IV TXA just before tourniquet
deflation. Blood loss in the hemovac drain and hemoglobin (Hb) concentrations were measured at 24 and 48 h (h),
and the number of blood transfusions and leg circumference measurements were recorded.
Results: At 48 h, the total blood loss in the hemovac drain was 445 mL in group 1 vs. 520 mL in group 2 (p = 0.
081) and the corresponding declines in Hb were 1.85 g/dL vs. 1.87 g/dL (p = 0.84). 16 patients received blood
transfusions: 9 vs. 7 in groups 1 and 2, respectively (p = 0.928). There were no differences in thigh and lower leg
circumferences, pain scores, knee flexion at discharge date and lengths of hospital stay. There were no clinically
detected venous thromboembolic events.
Conclusion: This pilot study has shown promising results for peri-articular TXA during TKA. Additional, larger
studies are needed to confirm our results and be powered to show differences in efficacy and safety of peri-
articular vs. IV TXA.
Trial registration: ClinicalTrials.gov Identifier NCT02829346. Retrospectively registered: 07/11/2016.
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Background
Postoperative bleeding in total knee arthroplasty (TKA),
which can result in hypovolemic shock and the need for
allogenic blood transfusions, is a major concern for ortho-
pedic surgeons. Several strategies are used to reduce post-
operative blood loss, including preoperative autologous
blood transfusions, hemoglobin raising agents, intraopera-
tive tourniquets, cell savers, intravenous (IV), and topical
tranexamic acid (TXA) [1–7]. TXA is an antifibrinolytic
agent that inhibits the conversion of plasminogen to
plasmin and also acts as a plasmin inhibitor. This results
in inhibition of the breaking down of fibrin blood clots (fi-
brinolysis) [8] and fibrin clot stabilization rather than the
promotion of clot aggregation [9, 10]. Plasmin activation
due to tissue trauma increases after release of the surgical
tourniquet and increased fibrinolysis [8, 11, 12].
IV TXA is commonly used intravenously for reducing
blood loss and blood transfusions following TKA. Blood
loss reduction varies from 10 % to 70 % compared to
control groups not receiving TXA [13–15]. However,
there are reports of thrombus formation associated with
IV TXA [16, 17]. Topical TXA applications have been
reported as another method to reduce blood loss and
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are associated with fewer systemic side effects compared
to IV TXA [6, 7, 18–21]. Topical TXA is usually applied
by soaking TXA in the operating field and washed after
period of time or left to drain out following wound clos-
ure and drain insertion. Topical TXA is only has superfi-
cial contact with the bleeding surface and for a limited
period of time. We do not know the effect of topical
TXA on polyethylene and this needs the further study.
Another approach could be peri-articular TXA injec-
tions which would act directly on the injured tissue and
for a longer duration compared to topical and IV TXA.
This may result in better reduced blood loss comparable
or better than topical or IV TXA but without the potential
systemic toxicity of IV TXA [22, 23].
Given the lack of data on peri-articular TXA, we
evaluated the benefits and toxicity of peri-articular
TXA compared to standard IV TXA and report the
results, herein.
Methods
This prospective, randomized trial was conducted from
October 2012 to October 2013, and approved by the
Ethics Committee, Institutional Review Board of Tham-
masat University (Registry #MTU-EC-OT-0-096/54). All
patients had been provided with written, informed con-
sent prior to their participation in the study.
The study inclusion criteria were adult patients with
osteoarthritis in need of a TKA.
The exclusion criteria were the patients with inflamma-
tory arthritis, post-traumatic arthritis, a history of or
current venous thromboembolic disease, any underlying
disease of haemostasis, cirrhosis, chronic renal failure,
patients on anticoagulants or strong antiplatelet drugs
(e.g. warfarin, clopidogrel), know allergy to TXA, defective
color vision, and a preoperative hemoglobin <10 g/dL or a
platelet count < 140,000 /uL3.
Study conduct
All patients underwent routine preoperative prepara-
tions. Patients on aspirin were asked to stop them at
least 7 days before the operation. The surgeries were
performed by a single surgeon (P.P.). The same surgical
technique was used throughout the study. After the
tourniquet was inflated, a limited medial parapatellar
skin incision (~10 cm length) was made beginning 2 cm
proximal to the superior pole of the patella and passing
along the medial border of the patella to the medial
border of the tibial tubercle. A medial parapatellar ap-
proach was used in all cases. Routine femoral (intrame-
dullary guide) and tibial (extramedullary guide)
preparations were carried out and the TKAs were per-
formed using the standard measured-resection tech-
nique. A cemented, posterior stabilized, fixed bearing
TKA prosthesis was used in all cases (Nexgen®; Zimmer,
Warsaw, IN, USA). No patellae were resurfaced but were
all denervated by electro cautery. Ten minutes prior to
deflating the tourniquet, sealed envelopes were opened
containing the randomized the allocated treatment. In
group 1, patients received 750 mg of peri-articular TXA
(Transamin®; OLIC Thailand Ltd, Bangkok, Thailand;
250 mg/5 mL, 15 cc total volume, Fig. 1) injection into
the soft tissue around medial capsule (5 ml), lateral cap-
sule (5 ml) and around the quadriceps muscle (5 ml). In
group 2, the patients received 750 mg of IV TXA
(250 mg/5 ml, 15 cc total volume, keeping within the
therapeutic range of 10–15 mg/kg/dose). One drain (Pri-
vac®; Primed Halberstadt Medizintechnik GmbH, Hal-
berstadt, Germany) was positioned in the lateral gutter
(Fig. 1) and the wound closed. The tourniquet was de-
flated following skin closure. The drain was clamped
and reopened three hours postoperatively. The drain
output was recorded at 24 and 48 h (post skin closure)
and removed at 48 h in all patients. Hemoglobin and
hematocrit levels were recorded at 24 and 48 h postop-
eratively. The criteria for blood transfusion were a
hemoglobin concentration < 10 g/dL or if patients had
any signs of anemia (e.g. chest pain that suggested from
cardiac origin, congestive heart failure, and unexplained
tachycardia or hypotension unresponsive to fluid re-
placement) at 24 or 48 h. One unit of packed red cells
was transfused per 1 g/dL of hemoglobin drop. No anti-
coagulant agents were used but postoperative foot pump
exercises and early ambulation were encouraged for all
patients. Patients with clinically suspected deep vein
thrombosis or a pulmonary venous thromboembolic
event (VTE) were sent for further investigation. Patients
were discharged when they were able to walk with walk-
ing aid more than 10 m, pain was controlled by oral an-
algesics and there was no continuous bleeding or oozing
from the wound.
The primary outcomes were: the volume of postopera-
tive blood loss in the drain, changes in hemoglobin con-
centrations, and the necessity for a blood transfusion. As
for secondary outcomes, we measured knee diameter for
swelling, local soft tissue complications, skin necrosis,
and clinically confirmed VTEs, and pain, using a Visual
Analogue Scales (VAS, 0 = no pain, 10 = the worst im-
aginable pain), knee flexion at discharge and the length
of hospital stay.
Knee swelling was measured circumferentially at the
thigh (taken at 10 cm above the upper pole of the pa-
tella) and the lower leg (taken at 10 cm below the lower
pole of the patella), and calculated as the differences in
the circumferences pre- and 48-h post-operation.
Sample size
The sample size was calculated based on the measured
postoperative blood loss. We assumed an alpha error of
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0.05 and applied an allocation ratio of 1. A sample size
of 30 participants, which allowed with a dropout rate of
10 % (3 participants), was calculated to provide a 80 %
power in detecting a difference of 150 mL or reducing
postoperative blood loss by 30 % in favour of the peri-
articular TXA injection (from 10 patients of our earlier
pilot study); we considered these parameters to be clinic-
ally relevant [24]. All statistical analyses were performed
using SPSS software version 17.0 (SPSS Inc, Chicago, IL,
USA). Differences in categorical variables were analyzed
by chi squared or Fisher’s exact test, as necessary, and
the unpaired ‘t’ test was used for normally distributed,
continuous variables.
Results
Of the 63 patients seen, two were diagnosed with in-
flammatory arthritis and one patient with post-traumatic
arthritis and so were excluded from the study. A total 60
patients were recruited, underwent a unilateral TKA and
completed the study. Half received either peri-articular
(group 1) or IV (group 2) TXA. Their ages ranged from
50–80 years. There were no significant differences pre-
operative Body Mass Index (BMI), hemoglobin, and
hematocrit level between the two groups (Table 1).
Blood loss measured in the drain postoperatively was less
in group 1 at both time points but the difference was not
statistically significant (Table 2). The changes in
hemoglobin and hematocrit were small and similar between
both groups as was the number of blood transfusions.
The postoperative leg, thigh swelling also showed no
significant differences (Table 3).
VAS for pain at the 24 and 48 h assessments, post-
operative knee flexion at discharge and hospital
lengths of stay were similar (Table 4).
No patients had clinical evidence of tense hemarthroses,
subcutaneous hematomas, peroneal nerve palsies, surgical
wound infections, skin necrosis or symptomatic VTEs up
to 14 days following the surgery.
Fig. 1 Peri-articular tranexamic acid injection (right knee) at a the medial gutter and medial capsule, b the lateral gutter and lateral capsule and c around
the quadriceps muscle. d One drain (Privac®; Primed Halberstadt Medizintechnik GmbH, Halberstadt, Germany) was positioned at the lateral gutter
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Discussion
TXA has been shown to be an effective antifibrinolytic
agent for reducing blood loss following TKA [8, 10].
However, IV TXA is a systemic therapy and requires
systemic distribution to exert its antibleeding effects.
Peri-articular TXA injection could, theoretically, be
more effective and cause less systemic toxicity like
thrombosis and systemic hypersensitivity reactions [25].
Given the lack of data, a randomized trial was needed
comparing peri-articular with the current standard treat-
ment of IV TXA.
Our study has demonstrated that the 750 mg of peri-
articular TXA injection group had less blood loss in the
drain and lower decreases in hemoglobin concentration
but a slight increase in the number of blood transfusion
rates which would be from lower initial hemoglobin level
in the peri-articular TXA injection group. Although
none of these differences were statistically significant,
the data hint that the antibleeding effects may have been
roughly similar. This was a pilot study using a “best
guess” dose. No dose ranging studies have been con-
ducted to determine the optimal peri-articular dose and
this is an area of future research.
There are the case reports of VTEs associated with IV
TXA administration which is concern to the surgeon
[16, 17]. Two recent meta-analyses of IV TXA in TKA
was unable to conclude definitively on its safety because
the studies were underpowered [26, 27]. Our study
found no VTE in either group but our patient numbers
were very small. The peri-articular TXA injection group
did not show signs of drug toxicity as evidenced by the
Table 1 Patient characteristics at baseline
Peri-articular group Intravenous group P
value*(n = 30) (n = 30)
Sex (male/female) 5/25 7/23 -
Age (y) 67.63 (+/− 7.96) 69.97 (+/− 7.55) 0.248
Weight (kg) 66.88 (+/− 11.29) 65.14 (+/− 9.32) 0.517
Height (cm) 155.73 (+/− 6.59) 156.77 (+/− 6.39) 0.539
BMI (kg/m2) 27.96 (+/− 4.99) 26.52 (+/− 3.71) 0.208
Hemoglobin (g/dL) 12.01 (+/− 1.27) 12.27 (+/− 1.30) 0.436
Hematocrit (%) 36.58 (+/− 3.63) 37.58 (+/− 3.49) 0.283
Values are number or mean (+/−Standard deviation = SD)
*P < 0.05 considered significant
Table 2 Blood loss and blood transfusions
Variable Group 1: Peri-articular group (n = 30) Group 2: Intravenous group (n = 30) P value*
Blood in Hemovac drain(ml)
24-h postoperative 300 (+/− 128) 334 (+/− 124) 0.279
48-h postoperative 145 (+/− 92) 186 (+/− 106) 0.094
Total 445 (+/− 158) 520 (+/− 175) 0.081
Hematocrit (%)
Preoperative 36.4 (+/− 3.6) 37.6 (+/− 3.5) 0.226
24-h postoperative 29.7 (+/− 3.4) 30.4 (+/− 4.0) 0.550
48-h postoperative 31.0 (+/− 2.7) 31.8 (+/− 3.4) 0.352
Total Hct change (%) (pre op – 48 hr) −5.4 (+/− 3.1) −5.8 (+/− 4.4) 0.730
Hemoglobin (g/dL)
preoperative 12.01 (+/− 1.27) 12.27 (+/− 1.30) 0.628
24-h postoperative 9.69 (+/− 1.19) 10.09 (+/− 1.50) 0.215
48-h postoperative 10.16 (+/− 0.98) 10.40 (+/− 1.28) 0.693
Total Hb change (g/dL) (pre op – 48 hr) −1.85 (+/− 0.95) −1.87 (+/− 1.37) 0.840
Total blood transfusion (PRC in unit) 12 8 -
Number of patients with blood transfusion 9 7 0.928
Values are number or mean (+/−Standard deviation = SD)
*P < 0.05 considered significant
Table 3 Thigh and leg circumferences (centimeters)
Peri-articular group Intravenous group P
value*(n = 30) (n = 30)
Thigh (cm)
Preoperative 44.25 (+/− 6.61) 43.63 (+/− 4.24) 0.627
Postoperative 46.30 (+/− 7.03) 45.10 (+/− 4.21) 0.398
Difference 2.05 (+/− 1.47) 1.47 (+/− 1.19) 0.093
Leg (cm)
Preoperative 35.20 (+/− 3.88) 33.57 (+/− 2.97) 0.069
Postoperative 36.57 (+/− 3.96) 34.70 (+/− 3.37) 0.052
Difference 1.39 (+/− 1.27) 1.16 (+/− 1.08) 0.491
Values are number or mean (+/−Standard deviation = SD)
*P < 0.05 considered significant
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lack of local physical signs, like excess bleeding, swelling,
and wound infections. This is a promising finding but
more studies are needed, including dose ranging studies
to ascertain if toxicity is dose related. Trying to detect if
there might be differences in risk of VTEs between peri-
articular and IV TXA would require very large sample
sizes and is best left to pharmacovigilance if peri-
articular TXA becomes an established practice. We ac-
knowledge our study’s limitations. The sample size was
small and so we were underpowered to detect uncom-
mon events like VTEs. Moreover, we were guided by
symptoms and signs of VTEs and did not actively seek
asymptomatic VTEs. A lack of resources precluded the
monitoring of serum TXA concentrations which could
have suggested under or over exposure of IV TXA. We
did not establish placebo group in the study, since the
administration of IV TXA is a standard protocol for our
patients and possible problem with ethical issues. The
previous prospective randomized controlled trial study
comparing IV TXA with placebo in the patients under-
gone TKA found significantly lower blood loss in IV
TXA group [13].
Conclusions
Our small pilot study has shown promising initial results
regarding peri-articular TXA injection. This, in primary
TKA, peri-articular TXA injection could be an alterna-
tive route of TXA administration. More research is
needed to determine the optimal TXA dose and define
better the risks and benefits.
Abbrevations
BMI, body mass index; TKA, total knee arthroplasty; VAS, visual analogue
scales for pain; VTE, venous thromboembolic event
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